Clinical Trials | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Biopharma and CROs to benefit from simplified access to global research sites
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Company is investing more than €100 million in the expansion of the Halle site
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Subscribe To Our Newsletter & Stay Updated
